Anavex Life Sciences Corp. (AVXL.OB) Reports That New Data Confirms Calcium Target Over-Expression May Be Involved In Causing Alzheimer's Disease
5/22/2014 9:25:26 AM
NEW YORK, May 22, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, welcomes new data published in the current issue of The Journal of Neuroscience that has favorable implications for ANAVEX PLUS, the Company's Alzheimer's disease drug candidate combination.
Help employers find you! Check out all the jobs and post your resume.
comments powered by